Modulation of NK, T, & B cell sub-populations by Pomalidomide predicts favorable progression-free survival (PFS): Results from a large randomized clinical trial in relapsed/refractory myeloma.

Autor: Rao, Prabhal, Samur, Mehmet, Talluri, Srikanth, Derebail, Sanika, Potluri, Lakshmi, Haas, Eric, Buonopane, Michael, Heubeck, Alexander, Fulciniti, Mariateresa, Lazo-Kallanian, Suzan, Hong, Kevin, Peluso, Teresa, john daley, Biyukov, Tsvetan, Beksac, Meral, Dimopoulos, Meletios A., mohamad hussain, Pierceall, William, Richardson, Paul G., Anderson, Kenneth C.
Zdroj: Clinical Lymphoma, Myeloma & Leukemia; Oct2019 Supplement, Vol. 19, pe167-e167, 1p
Databáze: Complementary Index
Externí odkaz: